Last checked at 13 Oct 2008 15:59
Notification of Major Interest in Shares
Monday 13 October 2008 - Medical Marketing International Group plc ("MMI" or the "Company") (AIM:MMG), the life sciences company focused on the development of drugs for cancer, received notification on 13 October 2008 from The Royal Bank of Scotland Group plc, that as at 9 October 2008, ABN AMRO Bank N.V (2.20%) and National Westminster Bank Plc (0.05%) have, in aggregate, decreased their interest from 1,811,250 to 1,431,250 ordinary shares of 0.2p each of the Company. The combined holding represents 2.25% of the Company's issued share capital of 63,665,557 ordinary shares.
Enquiries:
| Medical Marketing International Group plc | |
| Phil Cartmell, Non-executive Chairman | Tel: +44 (0) 1223 477 677 |
| Mark Burton, Chief Technical Officer | |
| Rob Sprawson, Chief Financial Officer | |
| FinnCap | |
| Sam Smith/Charlie Cunningham | Tel: +44 (0)20 7600 1658 |
| Financial Dynamics | |
| David Yates/Emma Thompson | Tel: +44 (0)20 7831 3113 |
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.
Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI electronically shall not apply to MMI.
-ends-